Literature DB >> 27431827

A systematic review on methods used to evaluate patient preferences in psoriasis treatments.

M Gutknecht1, M-L Schaarschmidt1, O Herrlein1, M Augustin1.   

Abstract

In the treatment of psoriasis and psoriatic arthritis, recently approved medications undergo the 'early benefit assessment' in Germany. Psoriasis treatments differ in a multiplicity of characteristics like side-effects, beneficial effect, cost and process attributes, which serve to evaluate the patient-relevant benefit compared to standard treatments. Patient preferences might help to aggregate the various patient-relevant outcomes into a single measure. In this context, besides the calculation of the quality-adjusted life-years (QALYs), the Institute for Quality and Efficiency in Health Care (IQWiG) refers to methods of multi-criteria decision making or preference evaluation like analytic hierarchy process and conjoint analysis. The objective was to give an overview of methods that have been used in international published studies to evaluate patient preferences in psoriasis treatments. The review is based on a systematic literature research on December 2014 in selected electronic databases, using the keywords 'psoriasis' and 'preferences' as well as the name of specific methods, known from the literature to evaluate patient preferences. The search resulted 389 hits without duplicates. 21 articles met the inclusion criteria. Depending on the study objective, preferences were elicited for health states, health state domains, treatment attributes or treatment alternatives focusing on different outcomes of preferences. Thereby, different methods were used in included studies. For this reason, there is no single outcome available that might be useful in the benefit assessment of the IQWiG. Willingness-to-pay, often included as part of a conjoint analysis, was the predominant method to elicit preferences. So far, the analytic hierarchy process has not been used in psoriasis studies. The use of this method in future studies might provide new essential knowledge in the evaluation of patient preferences in psoriasis treatments. However, a clear assignment when to use which method is not given by the IQWiG and should be prioritized.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2016        PMID: 27431827     DOI: 10.1111/jdv.13749

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  14 in total

1.  Assessing the Importance of Treatment Goals in Patients with Psoriasis: Analytic Hierarchy Process vs. Likert Scales.

Authors:  Mandy Gutknecht; Marion Danner; Marthe-Lisa Schaarschmidt; Christian Gross; Matthias Augustin
Journal:  Patient       Date:  2018-08       Impact factor: 3.883

Review 2.  Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.

Authors:  Juan Marcos Gonzalez
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

3.  Methods to perform systematic reviews of patient preferences: a literature survey.

Authors:  Tsung Yu; Nomin Enkh-Amgalan; Ganchimeg Zorigt
Journal:  BMC Med Res Methodol       Date:  2017-12-11       Impact factor: 4.615

4.  Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.

Authors:  Rosanne Janssens; Selena Russo; Eline van Overbeeke; Chiara Whichello; Sarah Harding; Jürgen Kübler; Juhaeri Juhaeri; Karin Schölin Bywall; Alina Comanescu; Axel Hueber; Matthias Englbrecht; Nikoletta Nikolenko; Gabriella Pravettoni; Steven Simoens; Hilde Stevens; Richard Hermann; Bennett Levitan; Irina Cleemput; Esther de Bekker-Grob; Jorien Veldwijk; Isabelle Huys
Journal:  Patient       Date:  2019-10       Impact factor: 3.883

5.  Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US.

Authors:  Chiara Whichello; Eline van Overbeeke; Rosanne Janssens; Karin Schölin Bywall; Selena Russo; Jorien Veldwijk; Irina Cleemput; Juhaeri Juhaeri; Bennett Levitan; Jürgen Kübler; Meredith Smith; Richard Hermann; Matthias Englbrecht; Axel J Hueber; Alina Comanescu; Sarah Harding; Steven Simoens; Isabelle Huys; Esther W de Bekker-Grob
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

6.  Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study.

Authors:  Eline van Overbeeke; Rosanne Janssens; Chiara Whichello; Karin Schölin Bywall; Jenny Sharpe; Nikoletta Nikolenko; Berkeley S Phillips; Paolo Guiddi; Gabriella Pravettoni; Laura Vergani; Giulia Marton; Irina Cleemput; Steven Simoens; Jürgen Kübler; Juhaeri Juhaeri; Bennett Levitan; Esther W de Bekker-Grob; Jorien Veldwijk; Isabelle Huys
Journal:  Front Pharmacol       Date:  2019-12-03       Impact factor: 5.810

7.  Multicriteria decision analysis (MCDA) in health care: a systematic review of the main characteristics and methodological steps.

Authors:  Talita D C Frazão; Deyse G G Camilo; Eric L S Cabral; Ricardo P Souza
Journal:  BMC Med Inform Decis Mak       Date:  2018-11-01       Impact factor: 2.796

8.  Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review.

Authors:  Rosanne Janssens; Isabelle Huys; Eline van Overbeeke; Chiara Whichello; Sarah Harding; Jürgen Kübler; Juhaeri Juhaeri; Antonio Ciaglia; Steven Simoens; Hilde Stevens; Meredith Smith; Bennett Levitan; Irina Cleemput; Esther de Bekker-Grob; Jorien Veldwijk
Journal:  BMC Med Inform Decis Mak       Date:  2019-10-04       Impact factor: 2.796

9.  Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives.

Authors:  Eline van Overbeeke; Valérie Forrester; Steven Simoens; Isabelle Huys
Journal:  Patient       Date:  2021-01       Impact factor: 3.883

10.  Measuring the importance of health domains in psoriasis - discrete choice experiment versus rating scales.

Authors:  Mandy Gutknecht; Marthe-Lisa Schaarschmidt; Marion Danner; Christine Blome; Matthias Augustin
Journal:  Patient Prefer Adherence       Date:  2018-03-15       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.